Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced the successful syndication of $500 million of incremental term loans under its existing senior secured credit facilities in connection with its acquisition of iNova. The incremental term loans will mature in April 2016 and have terms that are customary for this type of financing. The facility closed on December 19, 2011.
SOURCE Valeant Pharmaceuticals International, Inc.